Data Sheet (Cat.No.T38507)

TargetMol

Renzapride

Chemical Properties



CAS No. : 112727-80-7

Formula: C16H22ClN3O2

Molecular Weight: 323.82

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Renzapride (BRL 24924) is a mixed 5-hydroxytryptamine type 4 (5-HT4) agonist and 5-HT3 receptor antagonist.Renzapride can be used in the study of constipation-predominant irritable bowel syndrome (C-IBS).
Targets(IC50)	5-HT Receptor
In vitro	Renzapride was selective for serotonergic receptors and, in particular, had high affinity for human 5-HT(3) and guinea-pig 5-HT(4) receptors (K(i) 17 and 477 nm, respectively) [1].
In vivo	Renzapride(BRL 24924)(0.5-1 mg/kg) and another 5-HT1P antagonist, N-acetyl-5-hydroxytryptamine-5-hydroxytryptamine amide (5 mg/kg), significantly increased the rate of emptying of 51Cr-labeled liquid meals from the mouse stomach[2].

Solubility Information

Solubility	DMSO: 10 mg/mL (30.88 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (3.09 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0881 mL	15.4407 mL	30.8814 mL
5 mM	0.6176 mL	3.0881 mL	6.1763 mL
10 mM	0.3088 mL	1.5441 mL	3.0881 mL
50 mM	0.0618 mL	0.3088 mL	0.6176 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Meyers NL, et al. Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
Mawe GM, et al. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol. 1989 Sep;257(3 Pt 1):G386-96.
Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999;39(5):375-382.